To keep research teams informed of the latest updates to ClinicalTrials.gov, the University at Buffalo Clinical and Translational Science Institute (CTSI) will be providing news about the ...

The main market opportunities include identifying key locations for cost-effective clinical trials, understanding global trial success rates, and analyzing enrollment trends and competitive dynamics.

The "DNA Cancer Vaccine Clinical Trials, Development Technology Platforms & Market Opportunity Outlook 2026" report has been added to ResearchAndMarkets.com's offering. The global impact of cancer ...

CTSI Open Research Office sessions feature important topics that can aid those involved in the research process. Through the Open Research Office sessions, Clinical Research Facilitators collaborate ...

The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based ...

CNSide Diagnostics will present data from the FORESEE trial showcasing the CNSide CSF Assay Platform’s utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes.

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...

Opportunities lie in strategic investment formulation, identifying cost-effective locations for conducting trials, understanding global trial trends, and analyzing trial success rates. Insights into ...